Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K, whereas emtricitabine and tenofovir are eliminated by other renal transporters. However, although oxaliplatin is less nephrotoxic than other platinum drugs, renal function should be closely monitored due to a potential risk of additive nephrotoxicity.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking